18.05 -0.14 (-0.77%)
Before hours: 7:35AM EST
|Bid||0.00 x 1200|
|Ask||0.00 x 1400|
|Day's range||18.16 - 18.54|
|52-week range||12.43 - 20.42|
|Beta (5Y monthly)||1.09|
|PE ratio (TTM)||22.40|
|Forward dividend & yield||0.85 (4.67%)|
|Ex-dividend date||29 Sep 2020|
|1y target est||23.54|
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced that it achieved carbon neutrality in its value chain for its fiscal year 2019. This achievement was delivered by a continued focus on internal energy conservation measures, procurement of green energy, and investment in renewable energy certificates and high-quality, verified carbon offsets. These actions collectively address 100 percent of Takeda’s fiscal year 2019 scope 1, 2, and 3 emissions1 and represent a significant milestone in Takeda’s sustainability journey.
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") has earned an industry-leading position within the 2021 Access to Medicine (AtM) Index published today. Specifically the company achieved notable, high scores in all three technical areas evaluated by the Index, including being ranked first in Governance of Access. Takeda also demonstrated strong performance in the areas of health system strengthening, compliance and R&D capacity building, according to the Index.
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") today announced that it is one of only 16 companies to achieve global Top Employer® certification for 2021. In addition to receiving the global certification for the fourth consecutive year, Takeda was also certified as a Top Employer in four regions and 38 countries. This underscores the company’s commitment to creating an exceptional people experience for its global workforce.